ClinicalTrials.gov record
REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men
ACTIVE NOT RECRUITING · NCT04838769
Trial record
NCT IDNCT04838769
Status
ACTIVE NOT RECRUITING
Study type
INTERVENTIONAL
Phase
NA
Enrollment
155
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
REZŪM, alpha blocker and 5-alpha reductase inhibitor
Locations
Epworth Healthcare, Melbourne, Australia, Australian Clinical Trials, Wahroonga, Australia, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France, CHU d'Angers, Angers, France, CHU de Bordeaux, Bordeaux, France, CHU Grenoble, Grenoble, France, Centre Hospitalier Universitaire de Lille, Lille, France, Hôpital Privé La Louvière, Lille, France
Indexed topics
Last update
2026-08-10